Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
Accenture
Julphar
Farmers Insurance
US Army
Baxter
Teva
McKinsey
Cerilliant

Generated: January 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,980,171

« Back to Dashboard

Summary for Patent: 4,980,171
Title: Pharmaceutical composition for oral administration, based on a diphosphonic acid derivative
Abstract:The invention relates to oral pharmaceutical compositions comprising a diphosphonic acid derivative and sodium laurylsulfate in the amount of 1.5 to 6% by weight, relative to the diphosphonic compound.
Inventor(s): Fels; Jean-Pierre (Castelnau le lez, FR), Gromenil; Jean-Claude (Montbazin-Poussan, FR), Abramovici; Bernard (Juvignac, FR)
Assignee: Societe Anonyme dite : SANOFI (Paris, FR)
Application Number:07/333,966
Patent Claims: 1. A pharmaceutical composition for oral administration, based on a diphosphonic acid derivative of the formula ##STR2## in which R.sub.1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino or a dialkyl(C.sub.1 -C.sub.4)amino, and

R.sub.2 represents a halogen atom, a linear alkyl containing from 1 to 5 carbon atoms which is unsubstituted or substituted by a chlorine atom, a hydroxyl, an amino or a dialkyl(C.sub.1 -C.sub.4)amino, or R.sub.2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl or a thiomorpholin-4-yl,

or one of its pharmaceutically acceptable salts, which comprises from 1.5 to 6% by weight of sodium laurylsulfate relative to the diphosphonic acid derivative.

2. A pharmaceutical composition according to claim 1, wherein the diphosphonic acid derivative is selected from etidronic acid, piridronic acid, clodronic acid, pamidronic acid, 4-chlorophenylthiomethylenediphosphonic acid, 4-amino-1-hydroxybutylidenediphosphonic acid, 6-amino-1-hydroxyhexylidenediphosphonic acid, phenoxymethylenediphosphonic acid, thiomorpholinomethylenediphosphonic acid or one of their pharmaceutically acceptable salts.

3. A pharmaceutical composition according to claim 1, in which the diphosphonic acid derivative is 4-chlorophenylthiomethylenediphosphonic acid or its disodium salt.

4. A pharmaceutical composition according to claim 1, comprising from 100 to 500 mg of 4-chlorophenylthiomethylenediphosphonic acid or the equivalent amount of its disodium salt, and from 1.7 to 4% by weight of sodium laurylsulfate.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Moodys
Healthtrust
Fish and Richardson
McKinsey
Johnson and Johnson
US Army
Covington
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot